Cui et al. have explored the genomic abnormalities of 508 ESCC patients and proposed a classifying these tumors into three subgroups: NFE2L2-mutated, with poor prognosis; RTK-RAS-MYC-amplified (tumors with receptor tyrosine kinase/RAS amplification, such as EGFR or FGFR1 amplification, comprising about 50% of cases), with intermediate prognosis; and double-negative, with a better prognosis [35]. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.